Japan Approves First Drug to Slow Rare Liver Disease

Families dealing with progressive familial intrahepatic cholestasis can now access a treatment that does more than just manage symptoms. For the first time, doctors have a drug that may actually slow the liver damage that defines this rare childhood disease.

PFIC affects roughly 1 in 50,000 to 100,000 babies born worldwide. The genetic disorder prevents bile from flowing properly from the liver into the gut, causing it to build up inside liver cells instead.

Children with PFIC types 1 and 2 experience relentless itching across their entire body, jaundice, and progressive liver damage that often leads to transplant. Until now, doctors could only treat symptoms and provide nutritional support while watching the disease advance.

Associate Professor Hisamitsu Hayashi from the University of Tokyo led the research team that discovered an unexpected power in an existing drug. Sodium phenylbutyrate, already used to treat a completely different condition called urea cycle disorders, turned out to help liver cells move bile acids more effectively.

The drug increases special proteins called bile salt export pumps on the surface of liver cells. These pumps push bile acids out of cells and into bile, reducing the toxic buildup that damages the liver.

Getting from laboratory discovery to approved treatment took two decades. Hayashi and his team had to build knowledge from scratch because so little was understood about how PFIC progresses and how to measure treatment success.

They conducted an investigator-initiated clinical trial with six children in Japan. The results showed the treatment could slow liver damage in PFIC type 2 patients, providing enough evidence for regulatory approval for both PFIC types 1 and 2.

Why This Inspires

The journey to approval also created something bigger than one drug. The research team established the Comprehensive and Informative Registry System for Childhood Liver Disease, connecting patients, doctors, and researchers while collecting crucial data over time.

This platform is already helping pharmaceutical companies develop new treatments and conduct trials for other rare childhood liver diseases. What started as a way to solve one problem became a springboard for future discoveries.

Hayashi is careful to note that the drug won't work the same for everyone, and some patients may still need transplants eventually. Long-term monitoring will reveal who benefits most and how to use it effectively.

But for families who previously had no medical options to slow their child's disease, this approval represents real hope. The treatment broadens choices and gives doctors a tool they've never had before.

Twenty years of patient research just gave thousands of children worldwide a chance at healthier livers and better lives.